Biotechnology company Elicera Therapeutics AB (publ) announced on Monday that its drug candidate ELC-100 has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for treating pancreatic neuroendocrine tumours.
ODD supports the development of treatments for rare diseases, with benefits including tax credits for US clinical trials and potential fee waivers for marketing approval. In addition, ODD provides up to seven years of market exclusivity upon approval.
ELC-100 is based on an oncolytic virus and targets neuroendocrine cancer cells selectively. Elicera is currently conducting a Phase I/II trial to determine the maximum tolerated dose (MTD) and assess safety. The company completed patient recruitment for the trial's first part in fall 2024. Final data from this phase is expected in mid-2025.
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application
Polarean expands Ascend Imaging partnership to boost US market reach
Alto Neuroscience receives FDA Fast Track designation for ALTO-101
Calico Life Sciences' investigational treatment for ADPKD receives US FDA Fast Track Designation
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
Celltrion launches AVTOZMA IV in the United States following FDA approval
Vanda Pharmaceuticals agrees collaborative framework to resolve US FDA disputes
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance